An Open-Label, Phase 3 Trial of TAK-003, a Live Attenuated Dengue Tetravalent Vaccine, in Healthy US Adults: Immunogenicity and Safety when Administered During the Second Half of a 24-Month Shelf-Life.
HUMAN VACCINES & IMMUNOTHERAPEUTICS（2023）
Key words
Dengue fever,immunogenicity,live attenuated,safety,shelf-life,tetravalent,dengue vaccine
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined